Authors
Latest:
Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric CancerRutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.
Latest:
Dr Batchelor on the Rationale for Investigating Tirabrutinib in PCNSLTracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.
Latest:
Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic LeukemiaKey opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.
Latest:
Dr. Zurita-Saavedra on Augmenting Therapy Earlier in Prostate Cancer Treatment JourneyAmado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.
Latest:
Advice For Providers Caring for Patients With HR+/HER2- mBCVirginia Kaklamani, MD, and Elizabeth Diaz, PA-C, share advice for providers managing patients with HR+/HER2- metastatic breast cancer.
Latest:
Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced MelanomaIsabella C. Glitza Oliva, MD, PhD, MS, discusses the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.
Latest:
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer CareShridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.
Latest:
Examining the Promise of Multicancer Early Detection Tests: Looking to the FutureIn this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.
Latest:
Clinical Practice Pearls and the Future of SCLCThe panel shares clinical pearls for community oncologists treating small cell lung cancer.
Latest:
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell MalignanciesPatients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Latest:
Dr Kwendakwema on the Effects of Financial Toxicity on Treatment Costs in Patients With CancerNatasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.
Latest:
Dr Giannakis on the Initial Efficacy of CGX1321 With or Without Pembrolizumab in GI CancersMarios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.
Latest:
Dr. Munver on the Approval of Mitomycin Gel in Urothelial CancerRavi Munver, MD, discusses the approval of mitomycin gel in urothelial cancer.
Latest:
Patient Scenario 2: JAK2 Inhibitors in MyelofibrosisAfter reviewing the second patient scenario of myelofibrosis, experts from the John Theurer Cancer Center discuss the use of JAK inhibitors, specifically ruxolitinib, to manage patients in the frontline setting.
Latest:
Dr Bardia on the Efficacy and Safety of Dato-DXd in HR+/HER2– Breast CancerAditya Bardia, MD, MPH, discusses key efficacy results from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.
Latest:
The Future of Advanced Renal Cell Carcinoma ManagementDrs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.
Latest:
Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain MetastasesBrian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.
Latest:
Mapping Progress in Pancreatic Cancer Surgery: Leveraging New TechnologyIn this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.
Latest:
Dr. Shafique on the Goal of the CLASSICAL-Lung Trial With Pepinemab/Avelumab in NSCLCMichael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.
Latest:
Dr. Sanjana on the Use of Whole-Exome Sequencing to Predict Immunotherapy Response in Advanced TumorsNeville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.
Latest:
Dr. Lee on Treatment Considerations in Smoldering Multiple MyelomaSarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.
Latest:
Dr Mead on Unanswered Questions in the Treatment of MCLMonica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.
Latest:
Closing Thoughts on Evolving Antibody-Drug Conjugate LandscapeThe expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Latest:
Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C MelanomaBrian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.
Latest:
Dr. Cohen on Potential With CAR T-Cell Therapy in Medullary Thyroid CancerRoger B. Cohen, MD, is a professor of medicine at the Hospital of the University of Pennsylvania (Penn) and associate director of clinical research at Penn's Abramson Cancer Center. Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC).
Latest:
Dr. Khoury on the Importance of Differentiating Between BPDCN and AMLJoseph D. Khoury, MD, discusses the importance of differentiating between blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia.
Latest:
Dr Gondi on Prophylactic Cranial Irradiation With Hippocampal Avoidance in SCLCVinai Gondi, MD, discusses efficacy and safety findings from the phase 2/3 NRG-CC003 trial of prophylactic cranial irradiation in patients with small cell lung cancer.
Latest:
Dr. Masrouha on the Challenges of Surgical Removal of Chordoma TumorsKarim Masrouha, MD, discusses the challenges of surgically removing chordoma tumors.
Latest:
Dr Yang on the Results of the KEYNOTE-789 Trial in EGFR-mutant NSCLCJames Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.
